MedTrace Logo

Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse

NCT07595965 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-05-19

No results posted yet for this study

Summary

To evaluate the safety and tolerability of allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21) in patients with severe anti-aquaporin-4-immunoglobulin G positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD) relapse

Conditions

  • Neuromyelitis Optica Spectrum Disorder Relapse

Interventions

BIOLOGICAL

CE211NS21

baseline (D0), 4-week point (Visit 3), and 16-week point (Visit 6) for intrathecal administration of CE211NS21, Step 1 dose : 1x10\^6 cells/kg Step 2 dose : 2x10\^6 cells/kg; The Duration of follow up study following the administration of CE211NS21 is 5 years

Sponsors & Collaborators

  • Corestemchemon, Inc.

    lead INDUSTRY

Principal Investigators

  • sungmin Kim, MD, PhD · Seoul University hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2027-12-30
Completion
2028-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07595965 on ClinicalTrials.gov